Boston Scientific CEO Mike Mahoney on leadership, growth, innovation, and career-changing gut checks

In this episode, Boston Scientific Chair, CEO and President Mike Mahoney discusses his journey in the medical device industry, the qualities that make a great leader, and the strategies that have fueled the company's growth. Inspired by his grandfather, a cardiac surgeon, Mahoney initially wanted to become a doctor but ended up pursuing a career in business. Mahoney saw an opportunity at Boston Scientific when the company was struggling. Despite the risks involved, he took on the role of CEO because he believed in his skills and had a long-term vision for the company. Through the efforts of the company's leaders, a strong supply chain team, efficient operations, and a robust innovation pipeline, Boston Scientific has managed to maintain a 14% growth rate in a challenging market environment. Mahoney also highlights the company's focus on interventional medicine, which allows for quick procedures and same-day patient discharges, reducing the burden on hospitals. Mahoney further discusses the company's urology division, which has grown from a $500 million business to a $2 billion business. This growth has been fueled by a combination of organic R&D and acquisitions, creating a wide portfolio of differentiated products. Mahoney further elaborates on the company's diverse portfolio, mentioning the success of their peripheral vascular business and the potential of their diagnostics portfolio. Tune in to this episode for more on Mahoney’s strategies, challenges, and opportunities, offering valuable insights into the company's approach to driving growth and innovation in the medical device industry. Thank you to Resonant Link for sponsoring this episode of Boston Scientific Talks. For more information about Resonant Link go to www.Resonant-Link.com. Thank you for listening to the Boston Scientific Talks Podcast. Subscribe to this podcast on every major podcast platform.

There are no comments yet.

Please log in to write the first comment.